Imidapril

DRUG4 trials

Sponsors

Novartis Pharma AG, University of Pavia, Ministry of Health, Labour and Welfare, Japan

Conditions

Essential HypertensionHeart FailureHypertensionKidney, Polycystic, Autosomal DominantMicroalbuminuriaType 2 Diabetes Mellitus

Phase 2

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Ministry of Health, Labour and Welfare, JapanKidney, Polycystic, Autosomal Dominant

Start: 2009-07-31End: 2012-11-30Target: 160Updated: 2009-12-02

A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure

CompletedCTIS2023-504678-39-00

Novartis Pharma AGHeart Failure

Start: 2024-03-13End: 2024-11-08Target: 424Updated: 2024-11-08

Phase 3

Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension

University of PaviaEssential Hypertension

Start: 2008-03-31End: 2009-03-31Target: 60Updated: 2008-03-26

Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria

University of PaviaHypertension, Microalbuminuria, Type 2 Diabetes Mellitus

Start: 2010-10-31End: 2011-07-31Target: 206Updated: 2010-10-28